Table 3.
Characteristics of selected utility measurements
| Category | Characteristic | Number of utility measures (n = 218) | |
|---|---|---|---|
| Number | Percentage | ||
| Disease stage | Asymptomatic | 8 | 3.7% |
| Symptomatic | 15 | 6.9% | |
| AIDS | 56 | 25.7% | |
| Not reported/Combined* | 139 | 63.8% | |
| Measures | EQ-5D-3L | 53 | 24.3% |
| EQ-5D-5L | 3 | 1.4% | |
| HUI2 | 1 | 0.5% | |
| HUI3 | 20 | 9.2% | |
| 15 D | 2 | 0.9% | |
| SF-6D | 7 | 3.2% | |
| SG | 15 | 6.9% | |
| TTO | 17 | 7.8% | |
| VAS | 100 | 45.9% | |
| Settings | Developed countries | 168 | 77.1% |
| Developing countries | 50 | 22.9% | |
| Study design | Cross-sectional | 119 | 54.6% |
| Longitudinal | 99 | 45.4% | |
*Data were reported for patients at various disease stage categories.